Replies to post #132266 on Biotech Values

[mouton29]

This was just filed by Amphastar. The exhibit attached to it is the Wintrop US (Sanofi) press release announcing the withdrawal of the AG.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS
MOMENTA PHARMACEUTICALS, INC., et al.,
Plaintiffs,
v.
AMPHASTAR PHARMACEUTICALS, INC., et al.
Defendants.
)))))))))))
C.A. No. 1:11-cv-11681-NMG
DEFENDANTS’ NOTICE OF DEVELOPMENT IN GENERIC ENOXAPRIN MARKET
Defendants Amphastar Pharmaceuticals, Inc., et al., respectfully update the Court that on
November 30, 2011, Winthrop U.S., a business of Sanofi-Aventis U.S. LLC (“Sanofi-Aventis”)
suddenly announced that, based on unspecified “market conditions” that it was halting sales of
its authorized generic. See Exhibit A. Sanofi-Aventis did not specify when this discontinuation
will occur.

This news confirms that Sanofi-Aventis’s generic enoxaparin was in the market through
November 2011, as Defendants advised the Court earlier this week. See Dkt. Nos. 120-23.
Sanofi-Aventis’s announcement coincides with the deadline for Momenta to explain to the Court
its prior representations that Sanofi-Aventis left the market in October, before the preliminary
injunction was entered.

If Sanofi-Aventis implements withdrawal of its authorized generic, that will leave Sanofi-
Aventis’s high priced name-brand drug and Momenta’s high-priced generic version as the only
sources of this life-saving medication. Even with Sanofi-Aventi’s withdrawal from the generic
Case 1:11-cv-11681-NMG Document 125 Filed 12/01/11 Page 1 of 3
market, the Momenta-Sandoz agreement does not revert back to pre-AG launch and thus the
economics will not change.

Dated: December 1, 2011
Respectfully submitted,
________________/s/_______________
Anthony T. Pierce (admitted pro hac vice)
[e-mail]
Mark Mansour (admitted pro hac vice)
[e-mail]
AKIN GUMP STRAUSS HAUER & FELD LLP
1333 New Hampshire Avenue NW
Washington, DC 20036
Telephone: [phone]
Facsimile: 202.887.4288
Steven M. Bauer (BBO No. 542531)
[e-mail]
Isaac A. Hubner (BBO No. 677719)
[e-mail]
PROSKAUER ROSE LLP
One International Place
Boston, MA 02110
Telephone: [phone]
Facsimile: 617.526.9899
Jan P. Weir (admitted pro hac vice)
[e-mail]
STRADLING YOCCA CARLSON & RAUTH
660 Newport Center Drive, Suite 1600
Newport Beach, CA 92660
Telephone: [phone]
Facsimile: 949.725.4100
Counsel for Defendants Amphastar
Pharmaceuticals, Inc., International
Medication Systems, Ltd. and Watson
Pharmaceuticals, Inc.
Case 1:11-cv-11681-NMG Document 125 Filed 12/01/11 Page 2 of 3
CERTIFICATE OF SERVICE
I hereby certify that on the 1st day of December 2011, I caused a copy of the foregoing
Defendants’ Notice of Development in Generic Enoxparin Market to be electronically filed using
the CM/ECF system, which will then send a notification of such filing (NEF) to the following:
Courtney M. Schou
Eric J. Marandett
Jessica Gan Lee
Robert S. Frank , Jr.
CHOATE, HALL & STEWART LLP
Two International Place
100-150 Oliver Street
Boston, MA 02110
Telephone: [phone]
Facsimile: 617.248.4000
Counsel for Plaintiffs Momenta
Pharmaceuticals, Inc. and Sandoz, Inc.
Melissa Nott Davis
Sarah Chapin Columbia
Thomas P. Steindler
MCDERMOTT, WILL & EMERY LLP
28 State Street
Boston, MA 02109
Telephone: [phone]
Fax: [phone]
Counsel for Plaintiff Sandoz, Inc.
/s/ Steven M. Bauer
Steven M. Bauer (BBO No. 542531)
[e-mail]
PROSKAUER ROSE LLP
One International Place
Boston, MA 02110
Telephone: [phone]
Facsimile: 617.526.9899
Case 1:11-cv-11681-NMG Document 125 Filed 12/01/11 Page 3 of 3